Hillsdale Investment Management Inc. Acquires 715,229 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Hillsdale Investment Management Inc. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 89,403.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 716,029 shares of the company’s stock after purchasing an additional 715,229 shares during the quarter. Hillsdale Investment Management Inc. owned about 0.23% of Amneal Pharmaceuticals worth $7,167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in AMRX. GSA Capital Partners LLP lifted its stake in Amneal Pharmaceuticals by 64.2% in the third quarter. GSA Capital Partners LLP now owns 60,550 shares of the company’s stock valued at $606,000 after buying an additional 23,668 shares during the period. Vanguard Group Inc. increased its stake in Amneal Pharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock valued at $179,729,000 after purchasing an additional 403,582 shares in the last quarter. LSV Asset Management increased its position in Amneal Pharmaceuticals by 16.1% in the 3rd quarter. LSV Asset Management now owns 197,300 shares of the company’s stock valued at $1,975,000 after buying an additional 27,400 shares in the last quarter. Versor Investments LP acquired a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $578,000. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $1,608,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Truist Financial set a $15.00 price objective on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Finally, Barclays started coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.80.

Amneal Pharmaceuticals Price Performance

AMRX opened at $14.50 on Friday. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $15.42. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of 725.36 and a beta of 1.36. The firm’s fifty day moving average price is $13.55 and its two-hundred day moving average price is $11.54.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.